{"id":"lispro-low-mix","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The rapid-acting component (insulin lispro) is absorbed quickly to cover postprandial glucose excursions after meals, while the intermediate-acting component (insulin lispro protamine) provides longer-duration basal insulin coverage between meals and overnight. This combination allows for twice-daily dosing that approximates the body's natural biphasic insulin response to food intake and fasting periods.","oneSentence":"Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:37.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01773473","phase":"PHASE4","title":"Comparison of Insulin Mix25 Versus Mix50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":403},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT00664534","phase":"PHASE4","title":"Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00191178","phase":"PHASE4","title":"Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-08","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00420095","phase":"PHASE4","title":"A Study for Patients With Diabetes Mellitus (IOPA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":117},{"nctId":"NCT00551356","phase":"PHASE3","title":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Diabetes Mellitus Type 2","enrollment":53},{"nctId":"NCT00231725","phase":"PHASE3","title":"Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":370}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humalog Mix 75/25"],"phase":"marketed","status":"active","brandName":"Lispro Low Mix","genericName":"Lispro Low Mix","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}